Lilly buys Icos in $2.1B deal
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Lilly |
Icos |
$2.1B buyout |
The deal gives Lilly full control of ED drug tadalafil that the two companies have marketed jointly. |
|
Stiefel Laboratories |
Connetics Corporation |
$640M buyout |
Stiefel develops a number of prescription and non-prescription dermatological products and through the buyout, will gain Connetics' advanced therapies and topical delivery technologies. |
|
Genzyme |
AnorMed |
$580M buyout |
Genzyme has finally won the bidding war for AnorMed, gaining AnorMed's lead product, Mozobil, now in Phase III for hematopoietic stem cell transplantation. |
|
Cambrex |
Lonza |
$460M sale |
Cambrex is selling its bioproducts and biopharma business to Switzerland's Lonza Group and will use the money to pay a special dividend to shareholders. |
|
Merck |
Ambrilia Pharmaceuticals |
$232M licensing deal |
Canada's Ambrilia Pharmaceuticals has licensed its early-stage lead product to Merck for $17 million up front and up to $215 million in milestones. |
|
Serono |
Newron Pharmaceuticals |
$200M licensing deal |
Serono has won the worldwide development rights to Newron Pharmaceuticals' safinamide Parkinson's therapy. |
|
Merck KGaA |
Glenmark |
$144.2M licensing deal |
Merck KGaA will pay €25 million up front and up to €190 million in total to license Glenmark's DPP-4 inhibitor, GRC 8200, which is in Phase II trials. |
|
Schering-Plough |
Santarus |
$70M licensing deal |
The deal is for a low-dose version of the heartburn drug Zegerid. |